Created in 1996, the Office of Cancer Genomics (OCG) combines high-throughput genomics, and systems biology approaches to enhance the molecular understanding of cancer. The ultimate goal of OCG is to improve clinical outcomes for cancer patients.
Research over the last few decades has revealed that cancer is not a single disease, but rather many different diseases, each defined by a unique signature of molecular changes. To overcome the diverse genetic landscape of tumor cells and their surrounding microenvironment, better diagnostic tools are being developed to identify the unique molecular signature of individual patients’ tumors. Precision oncology, tailors diagnostic tools and drugs to the molecular signatures of patient’s tumors. This precision approach has already yielded improvements over standard chemotherapeutics in certain cancer subtypes. The research supported by OCG is working towards precision oncology by better defining molecular subtypes of various cancers, predominantly rare and/or high-risk diseases, and identifying potential treatment strategies that can be translated into effective patient care.
Through its collaborative initiatives, OCG aims to:
- Advance the understanding of the molecular mechanisms of cancer
- Develop reagents, technologies, tools and more biologically relevant tumor models
- Accelerate the translation of findings into the clinic
OCG is dedicated to supporting cancer genomics research by sharing molecular data from its programs to enhance understanding of cancer subtypes and promote rapid translation into improved cancer prevention, early detection, diagnosis and treatment through ocg.cancer.gov/ and the Genomics Data Commons.
Figure: This flowchart depicts how the four OCG-supported programs function and interact with one another to move toward the development of novel cancer therapeutics. View or download a 508 compliant version.